Evidence map›Paper›PMID 41368623›Full record

ArticleVirus evolution2025

The genetic architecture of HIV-1 virulence.

François Blanquart, Chris Wymant, Matthew Hall, Robert Power, Tanya Golubchik, Astrid Gall, Mariateresa de Cesare, George Macintyre-Cockett, Margreet Bakker, Daniela Bezemer and 23 more

Abstract read
In one paragraph

Article in Virus evolution, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

François BlanquartCenter for Interdisciplinary Research in Biology, CNRS, Collège de France, PSL Research University, 11 place Marcelin Berthelot, Paris 75231, France.ORCID https://orcid.org/0000-0003-0591-2466
Chris WymantPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford OX3 7LF, United Kingdom.ORCID https://orcid.org/0000-0002-9847-8226
Matthew HallPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford OX3 7LF, United Kingdom.ORCID https://orcid.org/0000-0002-2671-3864
Robert PowerBig Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford OX3 7LF, United Kingdom.
Tanya GolubchikSydney Infectious Diseases Institute, Faculty of Medicine and Health, University of Sydney; Biomedical Building, 1 Central Avenue, Eveleigh, NSW 2015, Australia.ORCID https://orcid.org/0000-0003-2765-9828
Astrid GallEMBO, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
Mariateresa de CesarePandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford OX3 7LF, United Kingdom.
George Macintyre-CockettPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford OX3 7LF, United Kingdom.
Margreet BakkerAmsterdam University Medical Centers, University of Amsterdam, Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Daniela BezemerStichting HIV Monitoring, Tafelbergweg 51, 1105 BD Amsterdam, The Netherlands.
Migle GabrielaiteInstitute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio al. 7, 10257 Vilnius, Lithuania.ORCID https://orcid.org/0000-0002-7959-8767
Swee Hoe OngWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom.ORCID https://orcid.org/0000-0002-3629-5387
Michelle KendallDepartment of Statistics, University of Warwick, Coventry CV4 7AL, United Kingdom.
Rafael SauterBig Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford OX3 7LF, United Kingdom.
Norbert BannertDepartment of Infectious Diseases, Unit 18, Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany.
Jacques FellaySchool of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Station 19, 1015 Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-8240-939X
M Kate GrabowskiDepartment of Pathology, Johns Hopkins School of Medicine, 446 Carnegie Building, 600 N Wolfe St, 21287 Baltimore MD, USA.
Barbara Gunsenheimer-BartmeyerDepartment of Infectious Disease Epidemiology, Unit 34 HIV/AIDS, STI and Blood-borne infections, Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany.
Huldrych F GünthardDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.
Pia KiveläDepartment of Infectious Diseases, Helsinki University Hospital, 00029 HUS, Helsinki, Finland.
Roger D KouyosDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.
Oliver LaeyendeckerDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, 855 North Wolfe St, 21209 Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-6429-4760
Rasmus L MarvigDepartment of Genomic Medicine, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-5267-3173
Karolin MeixenbergerDepartment of Infectious Diseases, Unit 18 Sexually transmitted bacterial Pathogens (STI) and HIV, Robert Koch Institute, Seestrasse 10, 13353 Berlin, Germany.ORCID https://orcid.org/0000-0001-6587-6394
Laurence MeyerInserm CESP U1018, APHP Bicetre Hospital, Paris Saclay University, 82 rue du general Leclerc, 94276 le Kremlin-Bicetre, France.
Ard van SighemStichting HIV Monitoring, Tafelbergweg 51, 1105 BD Amsterdam, The Netherlands.
David BonsallPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford OX3 7LF, United Kingdom.
Marc van der ValkStichting HIV Monitoring, Tafelbergweg 51, 1105 BD Amsterdam, The Netherlands.
Ben BerkhoutLaboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands.
Paul KellamDepartment of Infectious Disease, South Kensington Campus, Imperial College London, London, SW7 2AZ, United Kingdom.ORCID https://orcid.org/0000-0003-3166-4734
Marion CornelissenMedical Microbiology and Infection Prevention, Laboratory of Clinical Virology, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Peter ReissAmsterdam University Medical Center, University of Amsterdam, Global Health, Amsterdam institute for Immunology and Infectious diseases and Amsterdam Institute for Global Health and Development, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-7896-6428
Christophe FraserPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford OX3 7LF, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The virulence of Human Immunodeficiency Virus-1 (HIV-1) is partly determined by viral genetic variation. Finding individual genetic variants affecting virulence is important for our understanding of HIV pathogenesis and evolution of virulence; however, very few have been identified. To this end, within the "Bridging the Evolution and Epidemiology of HIV in Europe" (BEEHIVE) collaboration, we produced whole-genome HIV sequence data for 2294 seroconverters from European countries for a genome-wide association study (GWAS). We considered two phenotypes: (i) set-point viral load (SPVL), the approximately stable viral load from 6 to 24 months after infection, and (ii) the rate of CD4 cell count decline. We developed a GWAS method that corrects for population structure with random effects, accounts for two or more alleles at each locus, and tests for the effect of multiple genetic variants including single-nucleotide polymorphisms (SNPs), k-mers, insertions and deletions, within-host variant frequency, the number of rare point mutations, and drug resistance. We confirmed with this new approach that viral genomes explained 26% [95% CI 17%-35%] of the variance in SPVL, while they explained only 0.9% [0.0%-2.1%] of the variance in the rate of CD4 cell count decline. After correction for multiple testing, among all tested variants, only two significantly explained SPVL: an epitope mutation allowing escape from the host HLA-B

Indexed as

CTL escapegenome-wide association studyHIV-1polygenic traitvirulence

Identifiers

PMID41368623
PMCPMC12684972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.